Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

395
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
395
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.5K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

398
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WC1/WC2-Sre1 Transcriptional Cascade Controls Predation and Chlamydospore Formation in the Nematode-Trapping Fungus Arthrobotrys flagrans.

Microbial biotechnology·2026
Same author

Costs of HPV vaccination programs in low- and middle-income countries: A systematic review.

Journal of cancer policy·2026
Same author

SPINDOC functions as a mitotic molecular counter to coordinate spatiotemporal CENP-A assembly.

Cell reports·2026
Same author

Recommended intravenous infusion rate of sufentanil during induction of general anesthesia to prevent coughing: a randomized, single-blind, prospective clinical trials.

BMC anesthesiology·2026
Same author

Cascade active-targeting nanoplatform via multi-ligand regulation for spleen-selective mRNA delivery.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Evaluating the Effectiveness of an Enhanced Early Childhood Development Program Integrated Into Primary Health Care in China: Protocol for a Cluster Randomized Controlled Trial.

JMIR research protocols·2026

Related Experiment Video

Updated: Feb 22, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.5K

Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.

Shan Liu1,2, Xiaozhou Feng1, Rong Jin1

  • 1a Department of Neurosurgery , Pennsylvania State University College of Medicine , Hershey , PA , USA.

Expert Opinion on Drug Delivery
|September 26, 2017
PubMed
Summary

Nanotechnology enhances tissue plasminogen activator (tPA) delivery for acute ischemic stroke, improving efficacy and safety. Further research into nanocarrier characteristics and combined therapies promises advanced stroke treatment strategies.

Keywords:
Drug deliveryischemic strokenanocarriersnanoparticlesnanothrombolysisthrombolytic therapytissue plasminogen activator

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.4K

Related Experiment Videos

Last Updated: Feb 22, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.5K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.4K

Area of Science:

  • Biomedical Engineering
  • Nanomedicine
  • Neurology

Background:

  • Intravenous tissue plasminogen activator (tPA) is the sole FDA-approved treatment for acute ischemic stroke.
  • Current tPA therapy faces limitations including a narrow therapeutic window, variable efficacy, and risk of hemorrhage.
  • Progress in extending tPA's therapeutic window and finding alternatives has been limited.

Purpose of the Study:

  • To review the current applications of nanocarriers for tPA delivery in ischemic stroke treatment.
  • To discuss the advantages of nanotechnology in enhancing tPA efficacy and safety.
  • To explore future directions in tPA-based nanothrombolysis for stroke therapy.

Main Methods:

  • Review of existing literature on tPA biology, thrombolytic mechanisms, and nanocarrier applications.
  • Analysis of current challenges and potential future strategies in nanothrombolysis.
  • Discussion of the integration of nanocarriers with tPA for stroke treatment.

Main Results:

  • Nanocarriers offer significant advantages for tPA delivery, potentially improving treatment outcomes.
  • Further characterization of physicochemical properties and in vivo behavior of tPA-loaded nanocarriers is necessary.
  • Combination therapies involving nanothrombolysis and neuroprotection show promise.

Conclusions:

  • Nanotechnology presents a promising strategy to overcome the limitations of conventional tPA therapy for acute ischemic stroke.
  • Future research should focus on optimizing nanocarrier design and evaluating combined therapeutic approaches.
  • Theranostic nanocarriers offer potential for integrated diagnosis and treatment in stroke management.